Acute Graft Versus Host Disease Agvhd clinical trials

Explore recruiting acute graft versus host disease agvhd clinical trials.

Recruiting acute graft versus host disease agvhd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Acute Graft Versus Host Disease Agvhd trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ALL SCTped 2012 FORUM - Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia

Italy, Norway, Slovakia, Austria, Belgium, Germany +6 more

Phase II and Phase III (Integrated) EU CTIS Study details

Phase 2 Open Label Prospective Dose-Ranging Clinical Trial with Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients with Steroid -Refractory Acute Graft-versus-Host Disease

Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 2 Open Label Prospective Dose-Ranging Clinical Trial with Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients with Steroid -Refractory Acute Graft-versus-Host Disease

Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, single-blind trial to evaluate the safety and efficacy of apraglutide in subjects with Grade II to IV (MAGIC) steroid refractory gastrointestinal (GI) acute graft versus host disease on best available therapy.

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial.

Germany, Belgium, Italy, France, Austria, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomised, Open label, Controlled, Multicentre, Phase 2 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Paediatric Participants with Steroid refractory Acute Graft versus host Disease After Allogeneic Stem Cell Transplantation (BALDER Trial)

France, Spain, Germany, Poland, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Acute Graft Versus Host Disease Agvhd trials by city

Acute Graft Versus Host Disease Agvhd in Toronto Acute Graft Versus Host Disease Agvhd in Vancouver Acute Graft Versus Host Disease Agvhd in Montreal Acute Graft Versus Host Disease Agvhd in Calgary Acute Graft Versus Host Disease Agvhd in Edmonton Acute Graft Versus Host Disease Agvhd in Ottawa Acute Graft Versus Host Disease Agvhd in Winnipeg Acute Graft Versus Host Disease Agvhd in Quebec City Acute Graft Versus Host Disease Agvhd in Hamilton Acute Graft Versus Host Disease Agvhd in Kitchener Acute Graft Versus Host Disease Agvhd in London Acute Graft Versus Host Disease Agvhd in Halifax Acute Graft Versus Host Disease Agvhd in New York Acute Graft Versus Host Disease Agvhd in Los Angeles Acute Graft Versus Host Disease Agvhd in Chicago Acute Graft Versus Host Disease Agvhd in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease